A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease
2022-11-22
عنوان الدراسة
A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease
داعم الدراسة
Agios Pharmaceuticals, Inc.
دواء الدراسة
Mitapivat
رقم بروتوكول الدراسة
AG348-C-020
حالة الدراسة
Ongoing
موقع الدراسة
King Khalid University Hospital (Riyadh)
مرحلة الدراسة
2/3
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.